Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq
United States Miriam Weber Miller Aptevo Therapeuticsview Guillaume Van Renterghem Marvin White Exchange Commission
Source: finanznachrichten.de